TITLE

Review: The addition of infliximab and etanercept to methotrexate is effective in the long term for rheumatoid arthritis

PUB. DATE
September 2007
SOURCE
ACP Journal Club;Sept/Oct2007, Vol. 147 Issue 2, p42
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents information on a research that suggested that addition of infliximab (IFX) to methotrexate reduced symptoms and drug discontinuation in patients with rheumatoid arthritis (RA) in the long term. It is stated that etanercept (ETN) or IFX was compared in 30 patients with RA in the study. It is stated that several systematic reviews and randomized controlled trials (RCTs) evaluated clinical effectiveness of IFX. Relevant charts are also given.
ACCESSION #
27029969

 

Related Articles

  • Review: The addition of infliximab and etanercept to methotrexate is effective in the long term for rheumatoid arthritis: COMMENTARY. Meyerhoff, John // ACP Journal Club;Sept/Oct2007, Vol. 147 Issue 2, p42 

    The article presents the author's views on a review by M.E. Suarez-Almazor and colleagues of a research that suggested that addition of infliximab (IFX) and etanercept (ETN) to methotrexate was effective in the treatment of rheumatoid arthritis (RA). It is viewed that the review was outdated as...

  • Infliximab, etanercept worthwhile for RA in Spain? Salmon, Kimberly // PharmacoEconomics & Outcomes News;8/14/2004, Issue 459, p3 

    Discusses research being done on cost effectiveness of rheumatoid arthritis (RA) treatments in Spain. Reference to a study by J. B. Wong, et al and a study by B. Hernández-Cruz, et al both published in the June 12, 2004 issue of "Annals of the Rheumatic Diseases"; Findings of previous...

  • Infliximab/methotrexate/prednisone.  // Reactions Weekly;1/19/2008, Issue 1185, p20 

    The article presents a case study of a 62-year-old man with rheumatoid arthritis who developed cutaneous mucormycosis during treatment with infliximab, methotrexate and prednisone. After receiving infliximab, methotrexate and prednisone, he developed a small, tender nodule on his cheek. He later...

  • Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison. Baji, Petra; Péntek, Márta; Czirják, László; Szekanecz, Zoltán; Nagy, György; Gulácsi, László; Brodszky, Valentin // European Journal of Health Economics;May2014 Supplement, Vol. 15, p53 

    Objective: The aim of this meta-analysis was to compare the efficacy and safety of infliximab-biosimilar and other available biologicals for the treatment of rheumatoid arthritis (RA), namely abatacept, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, rituximab and tocilizumab....

  • Chelsea Therapeutics Reports on Phase II CH-4051.  // Biotech Business;Jul2012, Vol. 25 Issue 7, p5 

    The article reports on the Phase 2 trial that compares the efficacy and tolerability of the non-metabolized antifolate clinical trial drug, CH-4051, against antimetabolite and antifolate drug methotrexate in patients with rheumatoid arthritis. According to biopharmaceutical company Chelsea...

  • TAKING ON 'TiGER.'. Pisetsky, David S. // Arthritis Today;May/Jun2002, Vol. 16 Issue 3, p38 

    Presents the case of a patient with severe rheumatoid arthritis (RA). Treatment given to the patient prior to the clinical trial; Description of a clinical trial involving the methotrexate treatment of a patient with RA; Response of the patient to the drug.

  • Genentech's ACTEMRA(r) Monotherapy Showed Superior Improvement in Rheumatoid Arthritis Signs and Symptoms Versus Adalimumab Monotherapy.  // Biomedical Market Newsletter;3/7/2012, Vol. 21, p1 

    The article presents information on the ADACTA (ADalimumab ACTemrA) study according to which patients receiving ACTEMRA® (tocilizumab) experienced more decrease in disease activity after 24 weeks than those who were given adalimumab monotherapy. It is further mentioned that ADACTA study...

  • Pharmacogenetics in Treatment of Rheumatoid Arthritis. Kooloos, W. M.; Huizinga, T. W. J.; Guchelaar, H.-J.; Wessels, J. A. M. // Current Pharmaceutical Design;1/11/2010, Vol. 16 Issue 2, p164 

    Over the last decades important progress is being made regarding disease modifying anti-rheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis (RA). Nevertheless, a substantial part of the patients fail to achieve a good response and/or experience toxicity, which limits further...

  • Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis. Bejarano, Victoria; Conaghan, Philip G.; Quinn, Mark A.; Saleem, Benazir; Emery, Paul // Rheumatology;Oct2010, Vol. 49 Issue 10, p1971 

    Objective. To ascertain whether a 1-year remission induction therapy with an infliximab–MTX (INF–MTX) combination in patients with early RA provided sustained benefit after INF cessation compared with conventional treatment.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics